Noventra Pharma Tirzepatide (30mg Self-Mix – GLP-1 & GIP Peptide)

Tirzepatide is a dual incretin receptor agonist supplied in a lyophilized (self-mix) format, requiring reconstitution prior to use. It is investigated for its role in metabolic and endocrine signalling pathways through activity at glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

Tirzepatide has been studied in clinical and experimental contexts for its interaction with pathways involved in glucose regulation, insulin signalling, and energy balance.

Key Features:

• 30mg tirzepatide per vial

• Dual incretin receptor agonist: GLP-1 and GIP activity

• Lyophilized (self-mix) format requiring reconstitution

• Investigated for roles in metabolic and endocrine signalling pathways

• Studied in relation to glucose regulation and insulin-related processes

• Associated in research with energy balance and metabolic pathway activity

Suggested Use:
For research or controlled clinical use only. Protocols vary depending on study design and should be determined by qualified professionals in an appropriate setting.

Storage:

• Unreconstituted (lyophilized): Store in a cool, dry place (15–25°C), protected from light. Refrigeration (2–8°C) may be used for extended stability

• After reconstitution: Store at 2–8°C. Do not freeze

• Avoid repeated freeze–thaw cycles

• Use within a limited timeframe once reconstituted (based on formulation stability)

Important Information:
Tirzepatide has been studied in clinical settings for specific indications; however, this product should be used within appropriate professional and regulatory frameworks. Not recommended for individuals under 18, pregnant or breastfeeding individuals, or those with certain medical conditions. Ensure compliance with applicable regulations prior to use.